: A profitable firm trading at roughly 14 times earnings, well below the sector average of 26.
: Trading at a forward P/E of approximately 9.27, which is significantly lower than its 5-year mean.
: Focused on oncology with a high-performing lead drug, Cabometyx, and an estimated three-year revenue CAGR of 11.6%. cheap biotech stocks to buy
The biotech sector in April 2026 is seeing a resurgence driven by clinical milestones, FDA approvals, and a renewed interest in growth-oriented assets following a period of valuation compression. "Cheap" biotech stocks currently fall into two main categories: those with low nominal share prices (under $10) and larger-cap companies trading at historically low valuation multiples. Promising Stocks Under $10
: Trading at roughly 15 times earnings with double-digit increases in revenue and low debt. : A profitable firm trading at roughly 14
: Analysts view the stock as undervalued, underestimating its core business stability and growth from new product sales. Key 2026 Catalysts to Watch Best Biotech Stocks to Buy for April 2026
: Recently transitioned to a commercial-stage firm with an FDA-approved cancer drug; analysts see significant upside potential in 2026. The biotech sector in April 2026 is seeing
: Working on targeted radiotherapy; analysts project significant revenue growth in 2025-2026 if Phase 3 trials succeed. Undervalued Mid-to-Large Cap Leaders